Vivani Medical (VANI) Set to Announce Earnings on Thursday

Vivani Medical (NASDAQ:VANI) is anticipated to post its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Vivani Medical (NASDAQ:VANI) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. On average, analysts expect Vivani Medical to post ($0.30) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.

Vivani Medical Stock Up 5.1%

Shares of Vivani Medical stock opened at $1.12 on Tuesday. Vivani Medical has a 12 month low of $0.92 and a 12 month high of $1.66. The stock has a market cap of $101.47 million, a PE ratio of -3.21 and a beta of 2.51. The business has a fifty day simple moving average of $1.21 and a 200-day simple moving average of $1.25.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wall Street Zen downgraded Vivani Medical from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Vivani Medical currently has a consensus rating of “Hold” and a consensus target price of $3.75.

Vivani Medical Company Profile

Vivani Medical, Inc is a clinical-stage biopharmaceutical company developing miniature, subcutaneous drug implants designed to provide continuous delivery of medicines over extended periods. Its proprietary NanoPortal technology is intended to address challenges associated with conventional dosing, including frequent injections, daily administration and inconsistent medication adherence.

The company’s development programs have focused primarily on therapies for metabolic diseases. Its NPM-115 program is designed to deliver exenatide for chronic weight management, while NPM-119 is intended to provide continuous exenatide delivery for the treatment of type 2 diabetes.